BioMed X and Boehringer Ingelheim start new joint research group
BioMed X announced today the start of a new joint research group with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg. The focus of the group will be to identify novel regulatory pathways within the innate immune system, through understanding molecular mechanisms employed by bacteria to evade or modulate innate immunity.
Bacterial pathogens have co-evolved with their human hosts for millions of years. As a consequence they have developed mechanisms to evade the host’s innate immune response, partly by specific modulation of regulatory pathways in immune cells. Therefore, the central hypothesis of this research project is that molecular mechanisms employed by bacteria for immune modulation can be systematically characterized and interrogated as starting points for novel therapeutic immune modulation concepts to treat autoimmune diseases and cancer.
First members of the new research group including the group leader were identified using BioMed X’s unique global crowdsourcing approach followed by an intense innovation boot camp in Heidelberg. Dr. Bachir El Debs, who was previously working as a senior postdoctoral fellow at the European Molecular Biology Laboratory, is an expert in high-throughput microscopy and will lead the new research group at BioMed X. In the following 2-4 years of his project term, Dr. El Debs will use a unique and systematic experimental approach to elucidate pathogen-mediated modulation of innate immunity.
“We are excited to host the third group of our partner Boehringer Ingelheim at BioMed X”, said Christian Tidona, founder and Managing Director of BioMed X. “Our ongoing successful collaboration clearly indicates an exceptional level of mutual trust and confidence in our new innovation model.”
In 2015 BioMed X and Boehringer Ingelheim signed a framework agreement for early-stage preclinical biomedical research. Since that time, three research groups have been launched, the first one focusing on epigenetics and chronic obstructive pulmonary disease (COPD), the second on brain microcircuits in psychiatric diseases, and the third one on pathogen-mediated modulation of innate immunity.
Other news from the department science
Most read news
More news from our other portals
Last viewed contents
Nobilon advances first vaccine into human trials - Intranasal influenza vaccine begins Phase I clinical development
Raptor Pharmaceuticals and TorreyPines Therapeutics Receive Stockholder Approvals to Merge - Merger to Create NASDAQ-Listed Biopharmaceutical Company named Raptor Pharmaceutical Corp.
Nobel Prize for Physiology or Medicine 2020 Announced - Nobel Prize awarded to Harvey J. Alter, Michael Houghton and Charles M. Rice for the discovery of Hepatitis C virus
PharmAthene and SIGA Technologies sign definitive merger agreement
PerkinElmer announces third quarter results - GAAP Revenue of $548 million versus $563 million in the comparable prior period
Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria - Spin-out from the Universities of Glasgow and Oxford
Doped by food - Dopamine release regulates our eating behaviour
Turning fallen leaves into sustainably made paper - Ukrainian scientist selected as a finalist for the Young Inventors Prize 2024
Merck Celebrates Topping-Out Ceremony for New Membrane Production Plant - Investment of more than € 140 million creates approximately 55 new jobs
